Novartis Hikes Sandoz Sales Guide As Separation Edges Closer
As Sandoz Biopharm Contact Manufacturing Unit Moved To Novartis IM Segment
Novartis reported 8% top-line growth for its Sandoz unit during the first quarter of 2023, one of the last before it is separated into a standalone company.
